Impact of Mézières Rehabilitative Method in Patients with Parkinson’s Disease: A Randomized Controlled Trial

Table 3

Scales and clinical evaluation: comparison between groups at T1 (end of treatment) and T2 (follow-up) for pain, mobility (balance and posture), and disability (median and IQR, ).

Scales and clinical evaluations	Group B; (); T1		Group A; (); T1			Group B; (); T2		Group A; (); T2
	Median	IQR	Median	IQR		Median	IQR	Median	IQR
VAS (cm)	2.50	4.00	2.00	4.00	.20	3.00	4.00	1.50	4.00	.80
BBS	50.00	8.00	54.50	8.00	.10	50.00	5.00	51.50	7.50	.28
Trunk flexion test (cm)	10,00	10.00	10.00	11.80	.60	10.00	10.00	8.00	12.00	.50
FGA	11.00	6.00	9.00	6.00	.027	11.00	5.00	8.00	6.00	.03
MPAS	40.00	10.00	47.00	13.50	.30	40.00	10.00	47.00	14.00	.11
SMWT (min)	500.00	145.00	510.00	171.30	.90	500.00	130.00	480.00	277.50	.80
UPDRS Part I	7.00	7.00	7.50	7.00	.3	8.00	8.00	5.00	7.00	.05
UPDRS Part II	7.00	6.00	6.00	5.80	.40	6.00	8.00	6.00	5.50	.90
UPDRS Part III	11.00	8.00	10.00	8.50	.50	13.00	10.00	10.00	9.00	.20
UPDRS Part IV	2.00	5.00	2.50	4.80	.98	0.99	5.00	3.00	4.50	.95
UPDRS Total	49.00	0.00	49.00	12.50	.007	37.00	0.00	38.00	20.00	.80

value by Mann–Whitney test. Group A: Mézières treatment group; Group B: control group. IQR: interquartile range. VAS: Visual Analog Scale; BBS: Berg Balance Scale; FGA: Functional Gait Assessment; MPAS: Modified Parkinson’s Activity Scale; SMWT: six-minute walking test; UPDRS: Unified Parkinson’s Disease Rating Scale.